Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO
Recruiting now · Phase 2
Conditions studied: Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication, Platelet Dysfunction
In brief
The SURVIVE trial aims to test whether using an anti-thrombotic regimen involving cangrelor can reduce bleeding risk while maintaining effective antithrombotic effects in patients on VA-ECMO due to cardiogenic shock (CS)/ cardiac arrest (CA) who undergo percutaneous coronary intervention (PCI). The investigators plan to achieve this by starting cangrelor on top of systemic anticoagulation with bivalirudin at a low dose, regularly monitoring platelet function, and adjusting the dose based on the results of platelet function assay (Multiplate®) to guarantee effective platelet P2Y12 pathway inhibition to achieve optimal platelet inhibition. Platelet function assays will be performed at various time points throughout the treatment timeframe. Cangrelor will then be stopped at the end of VA-ECMO support, and patients will be transitioned to oral P2Y12- inhibitors as per clinical guidelines.
Key facts
- Study ID
- NCT06792643
- Run by
- IRCCS San Raffaele
- People needed
- 50
- Starts
- 2024-04-01
- Expected to finish
- 2025-12-31
- Last updated by the study team
- 2025-01-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or female patients aged ≥18 years;
- ACS-related CS/CA patients undergoing PCI (either with or without stent implantation) and needing VA-ECMO support;
- Patients who received pre-hospital aspirin intravenous loading dose or patients naïve to any anti-thrombotic agent;
- Written informed consent
You may not qualify if…
- Overt uncontrollable bleeding;
- Suspected intra-cranial haemorrhage;
- Patients who received any dose of any oral P2Y12-inhibitors;
- Patients with known history of stroke or Transient Ischaemic Attack (TIA);
- Patients with known hypersensitivity to the active substance (cangrelor) or to any of its excipients;
- Pregnancy.
Where it is running
- IRCCS San Raffaele Hospital — Milan, Italy, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.